Korean Pharma's Biosimilar Export Surge Meets a Weakening Won Headwind

DART Decoded Editorial Desk

Independent analysis of Korean DART filings & KRX market data · May 20, 2026

Korean bio-pharma stocks took a bruising on Wednesday as the broader KOSPI shed 1.57% to close at 7,157.15 and the tech-heavy KOSDAQ cratered 3.23% to 1,049.31. Against that backdrop, the sector's structural export story — built on biosimilar dominance and contract drug manufacturing — is colliding with a USD/KRW rate that has now breached 1,512, a level not seen in years. That currency dynamic cuts both ways: it inflates the won-denominated value of dollar-invoiced CDO contracts, while simultaneously compressing margins on euro-priced European biosimilar sales where much of the volume sits.

The Won's Double-Edged Sword for CDMO Giants

Samsung Biologics (KOSPI:207940) stands as the clearest example of the currency paradox. The Incheon-based contract manufacturer — the world's largest single-site CDMO by bioreactor capacity — invoices the vast majority of its revenue in US dollars, creating a natural tailwind when the won depreciates. Management has guided for full-year revenue growth north of 20% on the back of Plant 4's ramp and early-stage bookings for the under-construction Plant 5, which at 180,000 liters will alone exceed the total capacity of most European rivals.

Samsung Biologics' cumulative contracted backlog exceeded $11 billion at the end of Q1 2026, with North American clients accounting for roughly 60% of new deal flow — a structural dollar revenue hedge against won volatility.

The picture is more nuanced for Celltrion (KOSPI:068270). The Songdo group's biosimilar portfolio — led by Remsima SC (infliximab), Vegzelma (bevacizumab), and the recently launched Zymfentra in the US — is priced and tendered predominantly in euros and dollars across European and American markets. Celltrion completed its merger with Celltrion Healthcare in late 2023, consolidating the commercial operation, and is now navigating the first full fiscal year as a unified entity. The integration has brought one-time cost headwinds, but the combined gross margin profile is structurally superior: in-house manufacturing eliminates the third-party markup that dragged on Celltrion Healthcare's standalone numbers.

Celltrion's US Momentum and the Zymfentra Inflection Point

The market's near-term attention is locked on Zymfentra's US formulary positioning. The subcutaneous infliximab formulation received FDA approval in late 2023 and commercial launch proceeded through 2024, but pharmacy benefit manager (PBM) negotiations — the true gatekeepers of US biologics market share — are only now resolving into 2026 formulary decisions. Analysts tracking managed-care contracts suggest Zymfentra has secured preferred or parity status on several large national plans, a milestone that would shift the US revenue contribution from a rounding error to a material line item by Q3.

European biosimilar pricing, however, faces renewed pressure. Germany's AMNOG rebate negotiations for biosimilar oncology products tightened in early 2026, and UK NHS tender cycles are repricing infliximab and bevacizumab downward as multiple entrants — including Sandoz, Fresenius Kabi, and domestic European producers — compete aggressively. Celltrion's scale advantage in manufacturing cost must work harder to protect margins at lower reference prices.

SK Biopharmaceuticals: CNS Royalties as a Defensive Anchor

SK Biopharmaceuticals (KOSPI:326030) occupies a structurally different position from the biosimilar players. Its epilepsy drug cenobamate — marketed as Xcopri in the United States by its US subsidiary SK Life Science and as Ontozry in Europe through partner Angelini Pharma — generates royalty and milestone income largely insulated from biosimilar pricing wars. Xcopri prescription volumes in the US have grown consistently for twelve consecutive quarters, and the drug is approaching a commercially meaningful contribution to the parent's consolidated P&L after years of net losses during the launch phase.

The near-term catalyst for SK Biopharma watchers is the potential label expansion for Xcopri into primary generalized tonic-clonic seizures (PGTC), with a supplemental NDA outcome expected in the second half of 2026. Approval would broaden the addressable patient population and likely accelerate script growth among neurologists who currently restrict use to focal-onset indications.

Yuhan and Green Cross: Domestic Dynamics Under Pressure

Company	KRX Ticker	Primary Revenue Driver	Key Near-Term Catalyst	FX Sensitivity
Samsung Biologics	KOSPI:207940	CDMO contracts (USD-invoiced)	Plant 5 capacity booking rate	Positive on USD strength
Celltrion	KOSPI:068270	Biosimilar portfolio (EU/US)	Zymfentra US formulary wins	Mixed (USD positive, EUR negative)
SK Biopharmaceuticals	KOSPI:326030	Xcopri royalties (USD)	Xcopri PGTC label expansion NDA	Positive on USD strength
Yuhan	KOSPI:000100	Domestic pharma, Lazertinib milestones	Rybrevant+Lazertinib US reimbursement data	Moderate (milestone USD inflows)
Green Cross	KOSPI:006280	Vaccines, plasma-derived products	Influenza vaccine tender season (H2)	Low direct FX exposure

Yuhan (KOSPI:000100) remains one of the more quietly compelling stories in Korean pharma. Its co-developed lung cancer combination — lazertinib paired with amivantamab (Rybrevant), out-licensed to Johnson & Johnson — received FDA approval for first-line EGFR-mutated non-small cell lung cancer in 2024. The commercial ramp is now underway, and milestone payment triggers tied to cumulative net sales thresholds are becoming visible on a 12-18 month horizon. The company's domestic generics and over-the-counter franchise provides earnings stability while the oncology royalty stream matures.

Green Cross (KOSPI:006280) faces a tougher near-term setup. The plasma-derived therapeutics and vaccine specialist is heavily exposed to domestic tender pricing, which the Korean Health Insurance Review and Assessment Service has been ratcheting down as part of broader healthcare cost containment. International vaccine sales — primarily to UNICEF and PAHO channels for influenza and other indications — provide some offset, but the company's revenue visibility is inherently seasonal and tender-dependent rather than contract-backed.

DART Filings: No Sector-Specific Disclosures This Week

A review of filings submitted to the DART electronic disclosure system through May 20, 2026 reveals no material disclosures directly attributable to the five companies in scope. The available filings relate to construction, electronics, and robotics sectors. Investors should monitor for any late-week submissions — particularly from Celltrion, which has historically filed material contract announcements mid-quarter — and for any amendment to previously submitted securities registration statements that might signal equity or convertible bond financing activity.

Forward Catalysts: What to Watch Through Q3

Samsung Biologics Q2 earnings (late July): Plant 4 utilization rate and first Plant 5 contract disclosures will set the tone for the second half CDMO narrative.
Celltrion Zymfentra US prescription data (monthly): IQVIA weekly script data provides a real-time read on formulary traction ahead of any formal guidance revision.
SK Biopharmaceuticals Xcopri PGTC NDA decision (H2 2026): A positive ruling would represent the most significant label event for the drug since its initial US approval.
Yuhan lazertinib milestone tracking: J&J's Rybrevant+lazertinib net sales disclosures in quarterly earnings will determine when the next milestone tranche crystallises.
Korea HIRA drug pricing review (Q3 cycle): Annual reimbursement price adjustments affect Green Cross and Yuhan's domestic revenue base; decisions are typically published in August.
European EMA biosimilar approvals pipeline: Any new Celltrion biosimilar dossier rulings — particularly in the immunology and oncology pipeline — could re-rate the stock ahead of launch.

Disclaimer: Sector analysis is for informational purposes only. Not investment advice.

How this analysis was prepared

Source data: DART (Korea's Electronic Disclosure System), KRX market data, and global market feeds via yfinance. Korean filings were translated to English in full; numerical data is presented as filed. No third-party investment recommendations are referenced or implied.

Search This Blog

DART Decoded